No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation By Ogkologos - August 24, 2026 57 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SKYSCRAPER-03 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Study Improves the Quality of Biopsy Specimens for Cancer Research October 23, 2018 Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... February 3, 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 Load more HOT NEWS Seven Extra Years Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline... NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... How longer waiting times are impacting teens and young adults
